US biotin prices declined through February 2026 as weak demand and ample imports eroded seller leverage. Buying interest from formulators and brand owners remained subdued, while a 19 February safety headline heightened caution among medically monitored consumers, accelerating the late-month downturn. Demand weakness was broad-based across nutrition supplements, personal care, and healthcare segments. Formulators increasingly shifted toward B-complex blends and reduced per-unit biotin usage, lowering standalone demand. High import dependence limiting domestic pricing power. Ample on-dock supply and no logistics disruptions added further pressure. Although the recent Middle East conflict raised freight and energy cost concerns, its immediate impact was muted due to oversupply and weak consumption. Near-term sentiment remains bearish, with cautious procurement and sufficient stocks expected to keep prices under pressure unless demand recovers or supply chains tighten.
